Eli Lilly and Company

313.46+6.45+2.10%Vol 3.27M1Y Perf 52.75%
May 26th, 2022 16:05 DELAYED
BID313.35 ASK314.00
Open305.23 Previous Close313.46
Pre-Market- After-Market313.75
 - -  0.29 0.09%
Target Price
317.87 
Analyst Rating
Strong Buy 1.38
Potential %
1.41 
Finscreener Ranking
★+     43.83
Insiders Trans % 3/6/12 mo.
-33/-67/-67 
Value Ranking
     41.10
Insiders Value % 3/6/12 mo.
-75/-92/-92 
Growth Ranking
★★★★     57.19
Insiders Shares Cnt. % 3/6/12 mo.
-74/-92/-92 
Income Ranking
     33.38
Price Range Ratio 52W %
99.54 
Earnings Rating
Sell
Market Cap297.84B 
Earnings Date
28th Apr 2022
Alpha0.02 Standard Deviation0.07
Beta0.40 

Today's Price Range

303.61313.91

52W Range

195.50314.00

5 Year PE Ratio Range

-409.4043.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.89%
1 Month
9.95%
3 Months
24.96%
6 Months
20.39%
1 Year
52.75%
3 Years
168.40%
5 Years
301.61%
10 Years
757.29%

TickerPriceChg.Chg.%
LLY313.466.45002.10
AAPL143.783.26002.32
GOOG2 165.9249.13002.32
MSFT265.903.38001.29
XOM96.640.34000.35
WFC45.601.48003.35
JNJ179.46-0.1600-0.09
FB191.637.80004.24
GE77.012.48003.33
JPM129.442.20001.73
Financial StrengthValueIndustryS&P 500US Markets
0.80
1.30
0.62
1.77
21.00
Leverage Ratio 5.90
ProfitabilityValueIndustryS&P 500US Markets
74.40
24.10
29.70
21.00
20.93
RevenueValueIndustryS&P 500US Markets
29.32B
30.86
6.88
4.56
DividendsValueIndustryS&P 500US Markets
1.30
3.92
12.71
11.34
Payout ratio47.00
Earnings HistoryEstimateReportedSurprise %
Q01 20222.322.6212.93
Q04 20212.512.49-0.80
Q03 20211.981.94-2.02
Q02 20211.891.87-1.06
Q01 20212.121.87-11.79
Q04 20202.352.7517.02
Q03 20201.761.54-12.50
Q02 20201.581.8919.62
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.93-4.46Negative
9/2022 QR1.95-10.96Negative
12/2022 FY8.25-4.07Negative
12/2023 FY9.56-1.95Negative
Next Report Date-
Estimated EPS Next Report2.32
Estimates Count4
EPS Growth Next 5 Years %15.30
Volume Overview
Volume3.27M
Shares Outstanding950.16K
Shares Float789.64M
Trades Count55.98K
Dollar Volume1.02B
Avg. Volume2.97M
Avg. Weekly Volume2.98M
Avg. Monthly Volume2.99M
Avg. Quarterly Volume2.93M

Eli Lilly and Company (NYSE: LLY) stock closed at 313.46 per share at the end of the most recent trading day (a 2.1% change compared to the prior day closing price) with a volume of 3.27M shares and market capitalization of 297.84B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 19500 people. Eli Lilly and Company CEO is David A. Ricks.

The one-year performance of Eli Lilly and Company stock is 52.75%, while year-to-date (YTD) performance is 13.48%. LLY stock has a five-year performance of 301.61%. Its 52-week range is between 195.5 and 314, which gives LLY stock a 52-week price range ratio of 99.54%

Eli Lilly and Company currently has a PE ratio of 44.30, a price-to-book (PB) ratio of 30.43, a price-to-sale (PS) ratio of 9.81, a price to cashflow ratio of 33.70, a PEG ratio of 2.32, a ROA of 13.45%, a ROC of 26.20% and a ROE of 77.37%. The company’s profit margin is 20.93%, its EBITDA margin is 29.70%, and its revenue ttm is $29.32 Billion , which makes it $30.86 revenue per share.

Of the last four earnings reports from Eli Lilly and Company, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $2.32 for the next earnings report. Eli Lilly and Company’s next earnings report date is -.

The consensus rating of Wall Street analysts for Eli Lilly and Company is Strong Buy (1.38), with a target price of $317.87, which is +1.41% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eli Lilly and Company has a dividend yield of 1.30% with a dividend per share of $3.92 and a payout ratio of 47.00%.

Eli Lilly and Company has a Buy technical analysis rating based on Technical Indicators (ADX : 17.48, ATR14 : 8.96, CCI20 : 178.32, Chaikin Money Flow : 0.15, MACD : 4.40, Money Flow Index : 66.63, ROC : 9.72, RSI : 64.31, STOCH (14,3) : 98.54, STOCH RSI : 1.00, UO : 58.12, Williams %R : -1.46), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Anat Hakim (Option Excercise at a value of $0), Anne Nobles (Option Excercise at a value of $0), Daniel M. Skovronsky (Option Excercise at a value of $0), David A. Ricks (Option Excercise at a value of $0), Donald A. Zakrowski (Sold 1 660 shares of value $404 774 ), Ilya Yuffa (Sold 2 000 shares of value $480 030 ), Jacob S. Van Naarden (Option Excercise at a value of $0), Johna L. Norton (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Marschall S. Runge (Buy at a value of $49 850), Patrik Jonsson (Sold 1 348 shares of value $353 659 ), Stephen Fry (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (75.00 %)
10 (76.92 %)
11 (91.67 %)
Moderate Buy
1 (8.33 %)
1 (7.69 %)
0 (0.00 %)
Hold
2 (16.67 %)
2 (15.38 %)
1 (8.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.35
Strong Buy
1.17

Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

CEO: David A. Ricks

Telephone: +1 317 276-2000

Address: Lilly Corporate Center, Indianapolis 46285, IN, US

Number of employees: 19 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

66%34%

Bearish Bullish

65%35%

Bearish Bullish

61%39%

TipRanks News for LLY

Mon, 16 May 2022 01:55 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Bristol Myers (BMY) and Kodiak Sciences (KOD)

- TipRanks. All rights reserved.

Fri, 13 May 2022 20:55 GMT Eli Lilly & Co (LLY) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 01:15 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Eli Lilly & Co (LLY) and Humana (HUM)

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 04:35 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Alcon (ALC)

- TipRanks. All rights reserved.

Fri, 04 Feb 2022 10:38 GMT Eli Lilly Drops 2.4% Despite Beating Q4 Expectations

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 12:35 GMT Eli Lilly & Co (LLY) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits